Inhibits tumor growth; exerts immunologic effects by activating the cellular immunity to increase lymphocytes, eosinophils, platelets, and cytokines, including tumor necrosis factor, interleukin-1, and gamma interferon.

Metastatic renal cell carcinoma in adults.

Metabolized in the kidney; excreted in the urine. Serum half-life: 13 minutes after IV administration. Eliminated in 85 minutes.

♦ Adult: 600,000 IU/kg (0.037 mg/kg) given every 8 hours by a 15-minute IV infusion for a total of 14 doses. After 9 days of rest, repeat the schedule for another 14 doses, for a maximum of 28 doses per cycle. Doses may be held for toxicities. Retreatment may be given if response to treatment is noted after 4 weeks. The patient should have a rest period of at least 7 weeks from the date of discharge before retreatment.

♦ Pediatric: Safety and efficacy not established.

Supplied in powder for injection: single-use, preservative-free vials contain 22 million IU (1.3 mg) of aldesleukin. Reconstitute with 1.2 mL sterile water for injection. When reconstituted, each milliliter contains 18 million IU (1.1 mg) of aldesleukin. Do not reconstitute with bacteriostatic water or sodium chloride. Store powder and reconstituted solution in the refrigerator at 2° to 8°C (36° to 46°F). Do not shake or freeze. Discard unused portions. Administer reconstituted solution within 48 hours.